The results of those previous studies and the present study suggest that the ABL-RUNX2-MMP13 axis is involved in the metastatic program in some patients with breast cancer expressing ABL and/or RUNX2 and that the use of ABL-specific inhibitors may be a new therapeutic strategy in those patients. The gene discussed is RUNX2; the disease is breast carcinoma.